Company news

Poolbeg Pharma PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Poolbeg Pharma makes 'interesting addition to e...

December 15, 2022

Metabolic diseases oral delivery licence signed

December 14, 2022

Poolbeg Pharma receives initial results from hu...

December 12, 2022

POLB 001 LPS human challenge trial completed

December 12, 2022

Influenza AI model build completed

November 29, 2022

Poolbeg Pharma wins first non-dilutive grant fu...

November 21, 2022

Capital Markets Day

November 17, 2022

Poolbeg-led consortium awarded EUR 2.3m grant

November 15, 2022

Poolbeg Pharma makes virus 'breakthrough' using...

November 9, 2022

AI programme yields novel RSV drug targets

November 8, 2022

Upcoming events participation

October 21, 2022

CEO Share Purchase

October 6, 2022

POLB 001 US Patent update

October 4, 2022

Poolbeg licence of Melioidosis vaccine candidate

September 21, 2022

HC Wainwright Global Investment Conference

September 12, 2022

Interim Results

September 6, 2022

Notice of Results

August 31, 2022

POLB001 human challenge clinical trial to commence

July 20, 2022

Project update for AI model of RSV data

June 27, 2022

US patents granted for POLB 001 and POLB 002

May 26, 2022

TR-1: Notification of major interest in shares

May 23, 2022

GMP manufacturing contract signed

May 12, 2022

Attendance at European Melioidosis Congress

May 11, 2022

Distribution in Specie update

April 27, 2022

Key POLB 002 European Patent Granted

April 14, 2022

Distribution in Specie Shareholders

April 11, 2022

POLB001 Update - Clinical Trial Agreement Signed

March 31, 2022

Commencement of trading on US OTCQB market

March 30, 2022

AI deal signed with CytoReason

March 24, 2022

Notice of AGM

March 9, 2022

Final Results

March 3, 2022

Artificial Intelligence deal with OneThree Biotech

February 24, 2022

Confirmation of vaccine platform licence execution

January 31, 2022

Exclusive license of RNA-based immunotherapy asset

January 17, 2022

Poolbeg to develop oral vaccine delivery platform

December 16, 2021

Poolbeg signs option for new vaccine candidate

December 6, 2021

Scientific Advisory Board Appointment

November 25, 2021

Update on POLB 001 Clinical Development

November 18, 2021

PredictViral Patent Update

October 14, 2021

RNA sequencing ahead of AI analysis programme

October 7, 2021

September and October Investor conferences

September 13, 2021

POLB001 US Patent Update

September 7, 2021

TR-1

July 23, 2021

Admission to AIM

July 19, 2021

← Newer news releases

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.